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Intracellular pathogen sensor, NOD2, has been implicated
in regulation of wide range of anti-inflammatory responses
critical during development of a diverse array of inflammatory
diseases; however, underlying molecular details are still impre-
cisely understood. In this study, we demonstrate that NOD2
programs macrophages to trigger Notch1 signaling. Signaling
perturbations or genetic approaches suggest signaling integra-
tion through cross-talk between Notch1-PI3K during the
NOD2-triggered expression of a multitude of immunological
parameters including COX-2/PGE2 and IL-10. NOD2 stimula-
tion enhanced active recruitment of CSL/RBP-Jk on the
COX-2 promoter in vivo. Intriguingly, nitric oxide assumes
critical importance in NOD2-mediated activation of Notch1
signaling as iNOS/macrophages exhibited compromised
ability to execute NOD2-triggered Notch1 signaling responses.
Correlative evidence demonstrates that this mechanism oper-
ates in vivo in brain and splenocytes derived from wild type,
but not from iNOS/mice. Importantly, NOD2-driven acti-
vation of the Notch1-PI3K signaling axis contributes to its ca-
pacity to impart survival of macrophages against TNF- or
IFN--mediated apoptosis and resolution of inflammation.
Current investigation identifies Notch1-PI3K as signaling co-
horts involved in the NOD2-triggered expression of a battery
of genes associated with anti-inflammatory functions. These
findings serve as a paradigm to understand the pathogenesis of
NOD2-associated inflammatory diseases and clearly pave a
way toward development of novel therapeutics.
Macrophages as an important component of the innate
immune system often reside beneath the epithelium or muco-
sal surface of various organs that are entry points of diverse
pathogens (1). In this perspective, signaling cascades triggered
through pattern recognition receptors signify as critical
events regulating the activity of macrophages in terms of cy-
tokine or chemokine production, receptor expression, and
directed migration to secondary lymphoid organs for subse-
quent antigen presentation (2). These attributes often have a
major influence in determining the overall strength of the
immune response. Among pattern recognition receptors,
NOD-like receptors (NLR)3 represent a novel class of intra-
cellular pathogen recognition receptors and among NLRs,
nucleotide oligomerization domain (NOD) 2 is expressed spe-
cifically in monocytes/macrophages, T cells, and intestinal or
mucosal epithelial cells, in addition to other cells. The rate-
limiting step in NOD2 activation requires oligomerization of
the NOD domain effectuating in formation of a robust signal-
ing platform, a critical necessity in binding of effector kinases
and adaptor proteins including receptor-interacting protein 2
(RIP2) and transforming growth factor--activated kinase 1
(TAK1), which subsequently facilitates activation of NF-B
thus activating a wide range of immunomodulatory genes
(2–4).
Despite relevance in regard to regulation of inflammatory
responses or local immune homeostasis, the NOD2 contribu-
tion to adaptive immunity remains to be elucidated. Albeit a
integral component of bacterial peptidoglycan, MDP, a well
characterized ligand for NOD2, is known for its adjuvant
properties; interestingly, unlike many TLR agonists, its en-
gagement with NOD2 receptor preferentially drives Th2
skewed immune responses, which are generally associated
with the anti-inflammatory M2 phenotype of macrophages
(5–7). Importantly, natural mutations in the NOD2 gene have
been reported to be associated with genetic predisposition to
severe inflammatory diseases like Crohn disease, asthma,
chronic inflammatory bowel disease etc. (8–10). Thus be-
cause of its wide implications, our aim is to understand the
nature of the molecular signaling events that control the
NOD2-triggered immune responses.
Notch signaling effectuates important roles not only in the
development of the immune system, but also critically in cell
fate judgments among fully differentiated immune cells in-
cluding macrophages or dendritic cells (11–14). The Notch
pathway is characterized by juxtacrine ligand-receptor inter-
actions between adjacent cells, and macrophages are known
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to express Notch ligands as well as receptors, thus possessing
the capacity to both induce and respond to Notch signals.
Upon productive engagement of Notch receptor with its cog-
nate ligand-like Jagged1 on cell membrane of adjacent macro-
phages, the -secretase complex generates release of the
Notch intracellular domain (NICD/Cleaved Notch) by pro-
teolytic processing from the cell membrane. NICD upon
translocation to the nucleus binds and complexes with CSL/
RBP-Jk, a DNA-binding protein that normally associates with
Notch target gene promoters along with several co-repres-
sors. This results in coordinated recruitment of transcrip-
tional co-activators like mastermind, p300, and/or CBP
(CREB-binding protein) with simultaneous displacement of
co-repressors, leading to CSL/RBP-Jk-dependent transcrip-
tion of target genes (15, 16). Interestingly, because of signifi-
cant cross-talk among diverse signaling platforms, CSL/
RBP-Jk independent activation of its target genes by Notch
has also been documented (17–20). However, the importance
of the functional significance of Notch signaling in cytosolic
immune surveillance mediated by NLR-like NOD2 remains
unexplored.
Herein, we demonstrate a potential role for NOD2 in acti-
vating Notch1 signaling by virtue of directed regulation of
Jagged1 expression in macrophages. Importantly, signaling
perturbations or genetic approaches implicated a critical role
of cross-talk among members of Notch1-phosphoinositide
3-kinase (PI3K) in NOD2-mediated anti-inflammatory im-
mune responses, including the expression of cyclooxygen-
ase-2 (COX-2) and IL-10, in macrophages. Correlative evi-
dence demonstrates that this mechanism operates in vivo as
MDP, a known NOD2 agonist, triggered the expression of
activated Notch1, Jagged1, or its target gene COX-2 in brain
or splenocytes of mice. Importantly, we demonstrate that the
NOD2-driven activation of the Notch1-PI3K signaling cas-
cade is instrumental in protection of macrophages against
TNF- or IFN--triggered apoptosis. Briefly, the current in-
vestigation identifies a novel role for Notch1 signaling in or-
chestrating functional attributes of NOD2 activation in an
immunological milieu as well as in modulation of a distinct
set of innate immunological parameters including COX-2 in
innate immune cells.
EXPERIMENTAL PROCEDURES
Cells and Mice—Peritoneal macrophages were isolated
from peritoneal exudates of C57BL/6 or iNOS/ C57BL/6
mice maintained at the central animal facility, Indian Institute
of Science. The RAW 264.7 mouse macrophage cell line was
cultivated in DMEM (Sigma) supplemented with 10% heat
inactivated FBS (Sigma). All studies involving macrophages
were performed utilizing mice peritoneal macrophages with
the exception of transfection experiments, which were per-
formed on RAW 264.7 macrophages. Mouse bone marrow-
derived dendritic cells were generated as described previously
(21). All studies were carried out with approval from the Insti-
tutional Ethics Committee for animal experimentation as well
as from the Institutional Biosafety Committee.
Reagents and Antibodies—General laboratory chemicals
were purchased from Sigma or Merck. Lipopolysaccharide-
free MDP was procured from Sigma. Anti--actin, anti-iNOS,
and anti-PGE2 antibodies were obtained from Sigma. Anti-
COX-2 and anti-proliferating cell nuclear antigen were pur-
chased from Calbiochem. HRP-conjugated anti-rabbit IgG
and anti-mouse IgG antibodies were obtained from Jackson
ImmunoResearch Laboratories. The anti-Thr70 phospho-eu-
karyotic initiation factor 4E-binding protein 1 (4EBP1), anti-
4EBP1, anti-Thr180/Tyr182 phospho-p38 MAPK, anti-p38
MAPK, anti-Thr202/Tyr204 phospho-ERK1/2, anti-ERK1/2,
anti-NF-B p65, anti-cleaved Notch1 or anti-NICD (Val1744),
anti-Tyr458 p85/Tyr199 p55 phospho-PI3K, anti-p85
PI3K, anti-Jagged1, anti-II Ser660 phospho-PKC, anti-Ser176
phospho-RIP2, anti-Tyr416 Src, anti-Src, and anti-Ser412 phos-
pho-TAK1 antibodies were purchased from Cell Signaling
Technology.
Treatment with Pharmacological Reagents—All pharmaco-
logical reagents were obtained from Calbiochem and were
reconstituted in sterile DMSO (Sigma) and used at concentra-
tions detailed under supplemental Table S1. 1% DMSO was
used as the vehicle control. In all experiments with inhibitors,
a tested concentration was used after careful titration experi-
ments assessing the viability of the macrophages using MTT
(3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bro-
mide) assay. In experiments with inhibitors, the cells were
treated with a given inhibitor for 60 min before experimental
treatment. Nitric oxide donor, SIN-1 (Sigma), was used at
concentration of 20 M.
RNA Isolation and Quantitative Real Time PCR—Total
RNA from treated macrophages was isolated by the TRIzol
method (Sigma) as per the manufacturer’s protocol, and
treated with RNase-free DNase (Promega). The cDNA syn-
thesis kit (Fermentas) was used for reverse transcription ac-
cording to the manufacturer’s protocol. A real time PCR am-
plification (Applied Biosystems) using SYBR Green PCR mix
(Finnzymes, Finland) was performed for quantification of tar-
get gene expression. All reactions were repeated at least three
times independently to ensure the reproducibility of the re-
sults. Amplification of the GAPDH housekeeping gene was
used as internal control. Primer sequences used in the current
study are detailed in supplemental Table S2.
Immunoblotting Analysis—Cells were washed with PBS and
scrapped off the culture dish and collected by centrifugation.
Cell pellets were lysed in RIPA buffer consisting of 50 mM
Tris-HCl (pH 7.4), 1% Nonidet P-40, 0.25% sodium deoxy-
cholate, 150 mM NaCl, 1 mM EDTA, 1 mM PMSF, 1 g/ml of
each aprotinin, leupeptin, pepstatin, 1 mM Na3VO4, 1 mM
NaF, and incubated on ice for 30 min. Whole cell lysate was
collected by centrifuging lysed cells at 13,000 g for 10 min
at 4 °C. Equal protein amounts from each cell lysate was sub-
jected to SDS-PAGE and transferred onto PVDF membranes
(Millipore) by semidry Western blotting (Bio-Rad). Nonspe-
cific binding was blocked with 5% nonfat dry milk powder in
TBST (20 mM Tris-HCl (pH 7.4), 137 mM NaCl, and 0.1%
Tween 20) for 60 min. The blots were incubated overnight at
4 °C with primary antibodies diluted in TBST with 5% BSA.
After washing with TBST, blots were incubated with anti-
rabbit or anti-mouse IgG secondary antibodies conjugated to
HRP for 2 h. After further washing in TBST, the immunoblots
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were developed with an enhanced chemiluminescence detec-
tion system (PerkinElmer Life Sciences) as per the manufac-
turer’s instructions.
Transfection Studies—RAW 264.7 cells were transfected
with 100 nM siRNA using Oligofectamine (Invitrogen) accord-
ing to the manufacturer’s instructions. Transfection efficiency
was more than 50% throughout the experiments as deter-
mined by counting the number of siGLO Lamin A/C positive
cells in a microscopic field using a fluorescent microscope.
72 h post-transfection the cells were treated as indicated and
processed for expression analysis. All siRNAs were obtained
from Dharmacon as siGENOMETM SMARTpool reagents,
which contains a pool of four different double-stranded RNA
oligonucleotides (siRNA). RAW 264.7 macrophages were
transiently transfected with AKT or p85 dominant-negative
(D/N) cDNA constructs using lowMr polyethylenimine
(Sigma).
Chromatin Immunoprecipitation Assay—Chromatin im-
munoprecipitation assays were carried out as described previ-
ously (22). Peritoneal macrophages were left untreated or
treated as indicated for 6 h. The cells were fixed with 1.42%
formaldehyde for 15 min at room temperature followed by
inactivation of formaldehyde with addition of 125 mM glycine.
Chromatin extracts containing DNA fragments with an aver-
age size of 500 bp were immunoprecipitated using anti-NF-B
or anti-NICD antibodies for NF-B and RBP-Jk ChIP, respec-
tively. Purified DNA was analyzed by quantitative PCR using
the SYBR Green method (Finnzymes). Regions with NF-B
and RBP-Jk binding sites in the mouse COX-2 promoter were
amplified using primer pairs, NF-B forward, 5-ttaaccgg-
tagctgtgtgcgt-3, reverse, 5-tctccggtttcctcccagt-3; and
RBP-Jk forward, 5-tcccgtgaaaagagttgctga-3, reverse, 5-ttcat-
ggaactaccctccgg-3. 28S rRNA was used as control in the PCR
and the primers were forward, 5-ctgggtataggggcgaaagac-3
and reverse, 5-ggccccaagacctctaatcat-3. All results were nor-
malized either by the respective input values or by amplifica-
tion of 28S rRNA. All ChIP experiments were repeated at
least three times.
In Vivo Challenge of Mice with MDP or SIN-1—C57BL/6 or
iNOS/ C57BL/6 mice utilized in the current investigation
were 5–6 weeks old and each in vivo experiment involved
three animals per group. For intracranial or intravenous chal-
lenge, 5 g of MDP or 20 g of SIN-1 were resuspended in 50
l of sterile PBS and then inoculated using 1-ml syringes and
a 26-gauge needle. Control mice were injected with 50 l of
sterile PBS using the same protocol. Before intracranial inocu-
lation, mice were anesthetized with intraperitoneal injection
of 80 l of ketamine (6 mg). Experimental mice were sacri-
ficed after 3 or 6 days of inoculations in the case of intrave-
nous and intracranial inoculation, respectively, and spleno-
cytes or brain tissues were harvested.
Immunohistochemistry—Microtome sections (4 m) were
cut from formalin-fixed, decalcified, and paraffin-embedded
tissue samples. These paraffin-embedded sections were first
deparafinized, followed by antigen retrieval with boiling 10
mM citrate buffer (pH 6.0) in a microwave for 10 min, treated
with 1% H2O2 for 10 min, incubated with 0.1 M glycine for 15
min, and blocked with 5% BSA for 1 h at room temperature.
Primary antibodies were incubated overnight and HRP-conju-
gated secondary antibodies for 90 min. The horseradish per-
oxidase reaction was detected with 0.05% diaminobenzidine
and 0.03% H2O2. Sections were counterstained with hematox-
ylin, dehydrated, and mounted. Stained tissue sections were
analyzed with a Leica DMLB microscope (Leica Microsys-
tems, Wetzlar, Germany). All experiments were performed
with appropriate isotype-matched control antibodies.
Nuclear and Cytosolic Subcellular Fractionation—Macro-
phages were harvested by centrifugation and gently resus-
pended in ice-cold Buffer A (10 mM HEPES (pH 7.9), 10 mM
KCl, 0.1 mM EDTA, 0.1 mM EGTA, 1 mM DTT, and 0.5 mM
PMSF). After incubation on ice for 15 min, cell membranes
were disrupted with 10% Nonidet P-40, and the nuclear pel-
lets were recovered by centrifugation 13,000 g for 15 min at
4 °C. The supernatants from this step were used as cytosolic
extracts. Nuclear pellets were lysed with ice-cold Buffer C (20
mM HEPES (pH 7.9), 0.4 M NaCl, 1 mM EDTA, 1 mM EGTA, 1
mM DTT, and 1 mM PMSF) and nuclear extracts were col-
lected after centrifugation at 13,000 g for 20 min at 4 °C.
Enzyme Immunoassay for PGE2—Enzyme immunoassays
for quantitation of PGE2 were carried out in 96-well microti-
ter plates (Nunc) utilizing the culture supernatant of treated
samples. Culture supernatants were incubated in assay plates
overnight at 4 °C followed by three washes with PBS. After
blocking with 1% BSA for 1 h at 37 °C, wells were incubated
with anti-PGE2 antibodies for 6 h at 37 °C followed by wash-
ing with PBS. The plates were further incubated with HRP-
labeled anti-rabbit secondary antibody for 1 h at 37 °C fol-
lowed by development with 3,3,5,5-tetramethylbenzidine.
The absorbance was measured at 492 nm using an ELISA
reader (Molecular Devices).
Measurement of IL-10 Levels—Enzyme immunoassay for
IL-10 in cell-free culture supernatants was carried out using
the IL-10 ELISA kit (Peprotech Asia, Israel) following the
manufacturer’s instructions. Briefly, assay plates were coated
with anti-IL-10 capture antibodies overnight at 4 °C followed
by incubation with 1% BSA for 1 h at 37 °C. After three
washes with PBST (0.05% Tween 20), plates were incubated
with cell-free culture supernatants for 2 h followed by three
washes with PBST and incubation with anti-IL-10 detection
antibodies for 2 h at 37 °C. The plates were further incubated
with streptavidin-HRP antibodies for 1 h at 37 °C followed by
development with 3,3,5,5-tetramethylbenzidine. The ab-
sorbance was measured in an ELISA reader (Molecular De-
vices) at 492 nm.
MTT Assay—1.5 103 macrophages/well were seeded in a
96-well plate. After 12 h of plating, the cells were treated as
indicated followed by addition of MTT (20 l of 5 mg/ml) 3 h
prior to completion of the experiment. MTT is a tetrazolium
salt that is converted by living cells into blue formazan crys-
tals. The cell-free supernatant was removed from the wells 3 h
after MTT addition and 200 l of DMSO was added to dis-
solve the formazan crystals and the absorbance was measured
at 550 nm in an ELISA reader (Molecular Devices).
Statistical Analysis—Levels of significance for comparison
between samples were determined by Student’s t test. The
data in the graphs are expressed as the mean S.E. Graphpad
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Prism 3.0 software (Graphpad Software) was used for all sta-
tistical analysis.
RESULTS
NOD2 Receptor Engagement Results in Activation of Notch1
Signaling through Induced Jagged1 Expression—NOD2 recep-
tor-mediated signaling could elicit a spectrum of cellular im-
mune responses that constitute cytosolic innate immune sur-
veillance, including the production of multifaceted effector
PGE2, a product of inducible COX-2 enzymatic activity (23).
Herein, we show that engagement of the NOD2 receptor by
its cognate ligand MDP culminates in the robust activation of
Notch1 signaling as evidenced by induced formation of the
cleavage product of Notch1 (NICD) (Fig. 1A). Importantly,
MDP induced Jagged1 expression, a Notch1 receptor ligand,
is critical for the NOD2-driven Notch1 signaling (Fig. 1B). As
a “proof of concept,” NOD2 engagement resulted in the acti-
vation of effector kinases downstream of NOD2, including
RIP2 and TAK1, in a time-dependent manner (Fig. 1C). To
assess the importance of NOD2 and RIP2 in activation of
Notch1 signaling, expression levels of NICD and Jagged1 ex-
pression were quantified in the presence of the pharmacologi-
cal inhibitor of RIP2, PP2. Although PP2 is known to inhibit
Src family protein kinases, it has been recently reported that it
inhibits RIP2 more potently (24). Furthermore, utilized con-
centrations of PP2 failed to inhibit phorbol myristate acetate-
triggered activation of Src in primary macrophages (supple-
mental Fig. S1A). In addition, we could not detect activation
of Src upon stimulation of NOD2, ruling out any possibility of
a nonspecific effect of PP2 on Src family kinases (supplemen-
tal Fig. S1B). In this regard, inhibition of the RIP2 kinase by
PP2 abrogated the MDP driven activation of Notch1 signaling
as quantified by NICD formation, Jagged1 expression, and
expression analysis of Notch1 signaling target genes, COX-2
and Hes1 (Fig. 1, D and E, data not shown). Furthermore,
siRNA-mediated knockdown of NOD2, RIP2, or TAK1 se-
verely compromised the NOD2-driven expression of NICD,
Jagged1, or COX-2 (Fig. 1, F and G, and supplemental Fig. S2,
A–C). From bioinformatic analysis, we identified six CSL/
RBP-Jk and five NF-B-binding consensus in mouse COX-2
promoter (25). As shown in Fig. 1H, NOD2 engagement re-
sults in enhanced recruitment of CSL/RBP-Jk or NICD and
NF-B to COX-2 promoter signifying the involvement of the
Notch1-driven signaling events upon NOD2 stimulation.
Concomitantly, signaling perturbations with the Notch1 acti-
vation inhibitor, -secretase inhibitor I (GSI-I), as well as
siRNA-mediated knockdown of Notch1 or CSL/RBP-Jk
clearly established the involvement of Notch1 in NOD2-trig-
gered expression of Notch1 target genes COX-2 or Hes1 (Fig.
1, I and J, and supplemental Fig. S2D, data not shown). Fur-
thermore, stable expression of NICD in RAW 264.7 macro-
phages resulted in augmented expression of Notch1 target
genes Hes1 or COX-2 (data not shown) (22). Intriguingly, re-
FIGURE 1. Stimulation of NOD2 byMDP activates Jagged1 expression and Notch1 signaling. A and B,mouse macrophages were treated with 200
ng/ml of MDP for the indicated time periods and expression of NICD (A) or Jagged1 (B) was analyzed by immunoblotting. C, activation of RIP2 and TAK1 by
MDP. D,macrophages were treated with the RIP2 kinase inhibitor, PP2, prior to treatment with MDP followed by analysis of the protein levels of NICD and
Jagged1 by immunoblotting. E, RIP2 kinase inhibitor, PP2, curtailed MDP induced COX-2 expression. F, siRNA-mediated knockdown of NOD2, RIP2, and
TAK1 compromised the MDP-triggered activation of Notch1 and Jagged1 expression. G, reduction in MDP-induced COX-2 expression upon siRNA-mediated
knockdown of NOD2, RIP2, and TAK1. H, recruitment of (i) RBP-Jk/CSL or (ii) NF-B at COX-2 promoter was analyzed by the ChIP with antibodies specific to
NF-B or NICD in MDP-treated cell lysates. The active recruitment of NF-B or CSL/RBP-Jk was assessed by quantitative real time PCR (mean S.E., n 3).
I, pretreatment with GSI-I abolished MDP-induced expression of the Notch1 target gene, COX-2. J, transient transfection of Notch1 siRNA significantly abro-
gated MDP-triggered COX-2 expression in RAW 264.7 cells. The data represents results obtained from three independent experiments.Med, medium; *, p
0.05 versusmedium.
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cent studies have suggested that MDP as a NOD2 agonist has
the potential to drive Th2 responses in dendritic cells (5, 6).
Furthermore, when analyzed, activation of the NOD2 recep-
tor by its cognate ligand MDP resulted in induced formation
of NICD, expression of Jagged1, and a concomitant increase
in expression of the Notch1 target gene COX-2 in bone mar-
row-derived dendritic cells (supplemental Fig. S3A). Impor-
tantly, pretreatment of bone marrow-derived dendritic cells
with the RIP2 kinase inhibitor abolished the NOD2-triggered
activation of Notch1 signaling (supplemental Fig. S3A). These
findings strongly implicate a critical positive role for Notch1-
mediated CSL/RBP-Jk recruitment in the NOD2-driven anti-
inflammatory immune responses in macrophages as well as
dendritic cells.
NOD2 Receptor Triggering Effectuated the Signaling Cross-
talk among Notch1 and PI3K Pathways—Notch-specific ge-
netic signatures are critical not only in the development of
innate immunity, but also in imparting survival benefits to a
wide range of cell types (26, 27). In this perspective, Notch1
signaling-mediated survival effects frequently necessitate par-
ticipation of members of the PI3K pathway (27, 28). Impor-
tantly, delineation of the mechanisms involved in NOD2-
driven activation of the PI3K pathway, if any, remains
obscure.
To elucidate the involvement of NOD2 in PI3K signaling
activation, macrophages were pulsed with MDP and as shown
in Fig. 2A, NOD2 engagement triggered phosphorylation of
the p85 subunit of PI3K, 4EBP1, an important member of the
PI3K pathway. As described, stimulation of NOD2 resulted in
activation of RIP2 and TAK1 in a time-dependent manner
(Fig. 1C). In this perspective, to investigate the role for RIP2
kinase, NOD2-mediated activation of the PI3K pathway was
assessed upon pre-treatment of macrophages with the phar-
macological inhibitor PP2. As demonstrated, inhibition of the
RIP2 kinase by PP2 abrogated the NOD2-driven activation of
PI3K as quantified by phosphorylation of the p85 subunit of
PI3K or 4EBP1 (Fig. 2B). Extensive cross-talk among mem-
bers of the Notch1 and PI3K signaling cascades in terms of
genetic interactions, physical association between specific
members, or association to complex comprising unique cofac-
tors have been documented (22, 25, 27, 28). In this regard,
blockade of Notch1 signaling activation by GSI-I resulted in
marked inhibition of NOD2-driven activation of PI3K (Fig.
2C). Furthermore, in concurrence with these results, inhibi-
tion of PI3K by the p85 dominant-negative construct or phar-
macological inhibitor LY294002 and wortmannin; AKT by the
dominant-negative construct or AKT inhibitor; and mTOR by
rapamycin significantly attenuated NOD2-triggered Notch1-
PI3K-mediated COX-2 expression (Fig. 2, D and E). These
observations clearly implicate NOD2-driven activation of
Notch1 signaling in regulating the PI3K pathway thus exert-
ing direct effects in modulating specific molecular signatures
in macrophages.
Requirement of iNOS/NO in NOD2-driven Notch1-PI3K
Signaling—Recent studies have suggested that NOD/RIP2
signaling is crucial to iNOS/NO production in response to
bacterial infection, thus contributing to bacterial clearance
and host innate immune response. Interestingly, recent re-
ports have rendered the role of iNOS/NO in activation of
Notch1 signaling (22, 29). In this perspective, we addressed
FIGURE 2. Cross-talk of Notch1 signaling and PI3K pathway duringMDP-triggered activation of NOD2 signaling. A,MDP triggers phosphorylation of
p85 and 4EBP1 as analyzed by immunoblotting. B, inhibition of the RIP2 kinase by PP2 abolishes MDP-triggered phosphorylation of PI3K pathway members
p85 and 4EBP1. C, pharmacological inhibition of Notch1 activation by GSI-I-abrogated MDP-triggered phosphorylation of p85 and 4EBP1. D, transient trans-
fection of AKT dominant-negative (AKT D/N) or p85 dominant-negative (p85 D/N) constructs significantly reduced MDP-induced COX-2 expression in RAW
264.7 macrophages as assessed by immunoblotting. E, pharmacological intervention of PI3K signaling modulates MDP-triggered COX-2 expression. The
blots are representative of three independent experiments.Med, medium.
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whether NOD2 triggered expression of iNOS/NO to partici-
pate in activation of Notch1-PI3K signaling. As shown in Fig.
3A, NOD2 stimulation by MDP resulted in the robust iNOS
expression and inhibition of RIP2 kinase by the PP2 compro-
mised ability of NOD2 to induce iNOS expression. To vali-
date the importance of NOD2-triggered iNOS expression in
induction of NICD and Jagged1 expression, macrophages de-
rived from wild type (WT) and iNOS/mice, treated with or
without MDP, were analyzed. As represented in Fig. 3, B and
C, iNOS null macrophages demonstrated a marked inhibition
in NOD2-driven Notch1 activation and Jagged1 expression
compared with WT macrophages. Importantly, iNOS defi-
FIGURE 3. Involvement of iNOS in NOD2-mediated activation of Notch1-PI3K signaling. A, PP2 abolishes MDP-triggered expression of iNOS in mouse
macrophages. B,mouse macrophages derived fromWT or iNOS/mice were treated with MDP for the indicated time periods and protein levels of NICD
were analyzed by immunoblotting. C,macrophages derived fromWTmice were treated with MDP, whereas that from iNOS/mice were either treated
with MDP or with SIN-1 and expression levels of Jagged1 were analyzed by immunoblotting. D and E, reduced (D) phosphorylation of p85 and 4EBP1 and
(E) expression of COX-2 upon NOD2 stimulation by MDP in macrophages derived from iNOS/mice in comparison to WTmice. The data are representa-
tive of three independent experiments.Med, medium.
FIGURE 4. Essential role for iNOS/NO in NOD2-triggered activation of Notch1 signaling in vivo. A and B, expression analysis of (A) Notch1, Jagged1, and
COX-2 by quantitative real time PCR (mean S.E., n 3) or (B) NICD, Jagged1, and COX-2 by IHC in brain sections of WT mice injected with MDP and
iNOS/mice injected with MDP or SIN-1 intracranially. Hematoxylin (blue) was used for nuclear staining. IHC, immunohistochemistry; Exp., experiment;
*, p 0.05 versusWTMDP; **, p 0.05 versus iNOS/MDP.
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ciency caused a defect in the ability of NOD2 to trigger
Jagged1 expression and Notch1 activation was not due to the
general inability of cells to function, because analogues of
iNOS downstream mediators, SNAP or SIN-1 (NO donor),
could augment Jagged1 and NICD expression in iNOS-defi-
cient macrophages comparable with that in WT macrophages
(Fig. 3, B and C, data not shown). Significantly, NOD2-trig-
gered activation of the PI3K pathway was severely diminished
in iNOS null macrophages compared with WT macrophages
as evidenced by phosphorylation of the p85 subunit of PI3K
or 4EBP1 (Fig. 3D). Accordingly, the NOD2-Notch1-PI3K
signaling driven COX-2 expression was strikingly attenuated
in iNOS null macrophages (Fig. 3E). Noticeably, varying the
concentrations of MDP could not induce the expression of
COX-2 in iNOS-deficient macrophages. These findings con-
jecture the critical participation of the iNOS/NO pathway in
the NOD2-driven Jagged1 expression and activation of
Notch1 signaling in macrophages (Fig. 3E).
iNOS/NO Axis Is an Essential Link in NOD2-driven Notch1
Signaling in Vivo—To bring relevance to the biology of NOD2
in vivo, a suggested murine model to study the central nerv-
ous system and systemic inflammation was utilized (30, 31).
In this perspective, mice were challenged with MDP by an
intracranial or intravenous route and attempts were made to
validate the importance of iNOS in induction of Notch1 sig-
naling in vivo. In accordance with results obtained with
macrophages, iNOS deficiency in iNOS/mice severely
compromised potential of the NOD2 agonist to trigger aug-
mented expression of NICD, Jagged1, and COX-2 compared
with WT mice as evaluated by quantitative real time PCR and
immunohistochemistry based quantifications in the brain
sections (Fig. 4, A and B). Importantly, NO donor (SIN-1)
treatment of iNOS/mice in vivo rescued activation of
Notch1, expression of Jagged1, as well as Notch1 target genes,
COX-2 and Hes1 (Fig. 4, A and B, data not shown). Further-
more, results presented in Fig. 5A demonstrate that NOD2
engagement triggers the activation of Notch1 signaling in
splenocytes derived fromWT but not from iNOS/mice as
evidenced by expression levels of NICD, Jagged1, and the
Notch1 target gene, COX-2. However, intravenous inocula-
tion of iNOS/mice in vivo with the NO donor (SIN-1) res-
cued activation of Notch1 signaling (Fig. 5A). To carry out
recall experiments, mice were challenged with MDP followed
by restimulation of the splenocytes ex vivo. As presented in
Fig. 5B, ex vivo restimulation of NOD2 triggered the aug-
mented expression of NICD, Jagged1, as well as COX-2. In
agreement with previous results (Fig. 5A), the NO donor
(SIN-1) augmented activation of Notch1 signaling in ex vivo
restimulated splenocytes derived from iNOS/mice (Fig.
5B). These results strongly suggest that NO acts as an essen-
tial mediator of NOD2-dependent Notch1 signaling activa-
tion and is accountable for expression of specific anti-inflam-
matory molecular signatures like COX-2 in immune cells.
iNOS/NO Is Dispensable for the NOD2-driven PKC-MAPK
Signaling Axis—The onset and robust expansion of innate
immune responses initiated by innate immune receptors of-
FIGURE 5. Requirement of the iNOS/NO signaling axis during NOD2-mediated activation of Notch1 signaling in vivo. A, splenocytes fromWTmice,
injected with MDP, and iNOS/mice intravenously injected with MDP or SIN-1 were assessed for expression levels of NICD, Jagged1, and COX-2. B, in a
recall experiment, MDP and SIN-1 augmented the expression of NICD, Jagged1, and COX-2 upon restimulation of splenocytes ex vivo fromWT and iNOS/
mice, respectively. Data are representative of two independent experiments.
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ten involves regulatory effector proteins that act either up-
stream or downstream of activation of MAPK (32). Interest-
ingly, PKC is suggested to act as a critical regulatory kinase in
the initiation of diverse innate immune responses (33). Fur-
thermore, identification of signaling partners of the NOD2-
iNOS-Notch1-PI3K axis that are critical in driving the expres-
sion of anti-inflammatory molecular signatures, assumes
novel significance. In this perspective, we assessed the in-
volvement of PKC and MAPK during NOD2-induced COX-2
expression. As shown in supplemental Fig. S4A, NOD2 stimu-
lation triggered activation of PKC, ERK1/2, and p38 MAPK in
a time-dependent manner. The inhibition of RIP2 kinase by
PP2 abrogated the NOD2 driven activation of PKC, ERK1/2,
and p38 MAPK as quantified by phosphorylation of the re-
spective kinases (Fig. 6A). Interestingly, the pan-PKC inhibi-
tor RO31-8220 or chelerythrine significantly blocked the abil-
ity of NOD2 to trigger COX-2 expression, signifying the
important role for PKC in NOD2-driven signaling events (Fig.
6B). Additionally, NOD2 engagement by MDP markedly trig-
gered the phosphorylation of various PKC isoforms (data not
shown). To identify a role, if any, for the specific PKC iso-
form, we utilized well defined inhibitors for PKC, PKC,
PKC, PKC, and PKC. As shown, utilized inhibitors mark-
edly diminished NOD2-induced COX-2 expression, albeit to
varying degrees (Fig. 6B). Expectedly, blockade of ERK1/2 or
p38 MAPK, but not JNK1/2, during NOD2-driven signaling
cascades, significantly reduced the NOD2-stimulated COX-2
expression (Fig. 6C). Intriguingly, NOD2-driven activation of
PKC regulated activation of ERK1/2 and p38 MAPK down-
stream (Fig. 6D).
As described in Figs. 3–5, we have shown that iNOS/NO
acts as a key regulator of NOD2-mediated Notch1 signaling
activation as well as expression of Jagged1 and the Notch1
target gene, COX-2. In this regard, we explored whether
NOD2-mediated activation of PKC, ERK1/2, or p38 MAPK
requires the involvement of iNOS/NO by utilizing peritoneal
macrophages derived fromWT and iNOS/mice. The data
presented in Fig. 6E suggests that the ability of NOD2 to trig-
ger phosphorylation of PKC, ERK1/2, and p38 MAPK remains
unaltered in iNOS null macrophages in comparison to WT
suggesting iNOS activity-independent activation of PKC or
MAPK during NOD2 stimulation.
Signaling Integration through Cross-talk of iNOS-dependent
and -Independent Signaling Cascades during NOD2-triggered
Activation of NF-B—Several pro- or anti-inflammatory
genes’ promoters including COX-2 contain many cis-acting
consensus elements for NF-B and Notch1-mediated activa-
tion of its target genes often involves the active recruitment of
transcription factor NF-B (22, 25). In this perspective, we
show that NOD2 stimulation drives nuclear translocation of
NF-B in time-dependent manner with a concomitant decrease
in the cytosolic levels of NF-B (supplemental Fig. S4B). Accord-
FIGURE 6.Nitric oxide-dependent and -independent signaling cascades regulate NOD2-triggered COX-2 expression. A,mouse macrophages were
pretreated with PP2 followed by treatment with MDP and analysis of the activation status of PKC, ERK1/2, and p38 MAPK by immunoblotting. B, pan-PKC
inhibitors RO31-8220 and chelerythrine as well as isoform-specific inhibitors of PKC abolished the MDP-triggered COX-2 expression. C, analysis of the MDP-
triggered COX-2 expression upon pretreatment of macrophages with ERK1/2 inhibitor, U0126; p38 MAPK inhibitor; JNK1/2 inhibitor, SP600125. D, pretreat-
ment with the pan-PKC inhibitor chelerythrine abrogated MDP-triggered activation of ERK1/2 and p38 MAPK. E, analysis of MDP-induced activation of PKC,
ERK1/2, and p38 MAPK in macrophages derived fromWT and iNOS/mice. F, nuclear localization of p65 NF-B in MDP-treated WTmacrophages, with or
without pretreatment with PP2, GSI-I, or LY294002, or chelerythrine, U0126, or p38 MAP kinase inhibitor as well as in macrophages derived from iNOS/
mice. The blots are representative of three independent experiments.Med, medium.
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ingly, nuclear translocation of NF-Bwas abrogated upon inhibi-
tion of NOD2 signaling by PP2 (Fig. 6F). Expectedly, interference
in Notch1 signaling (GSI-I), activation of PI3K (LY294002), PKC
(chelerythrine), ERK1/2 (U1026), or p38MAPK (p38MAP ki-
nase inhibitor) reversed the NOD2 potential to trigger nuclear
translocation of NF-B from the cytosol (Fig. 6F). Blocking the
NF-B signaling pathway using Bay 11-7082, a specific inhibitor
of IB phosphorylation, markedly diminished the induced ex-
pression of NOD2/Notch1 responsive molecular signature,
COX-2 (supplemental Fig. S4C). Interestingly, the ability of
NOD2 to trigger nuclear translocation of NF-Bwas compro-
mised in iNOS null macrophages implicating iNOS activity de-
pendence in NOD2-mediated activation of NF-B (Fig. 6F).
Signaling Cohorts of NOD2 Regulate Expression of Anti-
inflammatory Cytokine IL-10—IL-10 is known to be up-regu-
lated following Notch1 activation by Jagged1 (34). Interest-
ingly, COX-2 is known to regulate IL-10 levels in
macrophages by virtue of induced secretion of PGE2 (35). Im-
portantly, NOD2 mutation associated with Crohn disease fails
to activate IL-10 expression (10). In this regard, our data sug-
gests that NOD2 activated the Notch1-PI3K and PKC-MAPK
signaling axis integrate together to activate NF-B, which
drives the activation/expression of the factors involved in
IL-10 expression. In this regard, functional activation of
NOD2 in macrophages led to enhanced secretion of PGE2
(25910 827 pg/ml). Furthermore, signaling perturbation
experiments involving inhibition of RIP2, Notch1, PI3K, PKC,
ERK1/2, p38 MAPK, and NF-B diminished the NOD2-trig-
gered PGE2 levels (Fig. 7A). Conversely, pharmacological inhi-
bition of RIP2, Notch1, PI3K, PKC, ERK1/2, p38 MAPK, or
NF-B led to abrogation of NOD2-triggered IL-10 expression,
although up to different levels (Fig. 7B and supplemental Fig.
S5A). Accordingly, pharmacological inhibition of RIP2 kinase
in bone marrow-derived dendritic cells abrogated NOD2-
triggered secretion of IL-10 and PGE2 (supplemental Fig. S5,
B and C).
NOD2-triggered Notch1 Signaling Attenuates TNF- or
IFN--mediated Apoptosis—Pro-inflammatory cytokines in-
cluding TNF- and IFN- are known to induce macrophage
cell death and tissue damage associated with various inflam-
matory diseases (36). In this regard, NOD2 as well as Notch1
are known to promote survival of a wide range of cellular sys-
tems (26, 27, 37). In this perspective, we explored the role of
NOD2-mediated activation of Notch1 and other signaling
cohorts in induced expression of a set of anti-apoptotic genes
by quantitative real time PCR. As demonstrated, NOD2 stim-
ulation triggered induced expression of Bcl-xL, cIAP1, and
XIAP (Fig. 8A). However, we could not detect any enhance-
ment in expression of another anti-apoptotic gene, Bcl2, con-
jecturing specificity of the system (data not shown). Signaling
perturbation experiments involving inhibition of RIP2,
Notch1, PI3K, PKC, and NF-B limited the potential of
NOD2 to trigger Bcl-xL, cIAP1, and XIAP expression (Fig.
8A). Conversely, inhibition of Notch1-PI3K or PKC-MAPK
signaling axis-mediated activation of NF-B compromised the
ability of NOD2 to protect macrophages against TNF-- and
IFN--induced cell death (Fig. 8, B and C). Together, these
results eloquently suggest that NOD2-driven Notch1-PI3K
activation, in conjunction with the PKC-MAPK signaling axis,
exert cooperative regulation of a distinct set of effector func-
tions in macrophages.
FIGURE 7. Critical role for NOD2-mediated activation of the Notch1-PI3K and PKC-MAPK signaling axis in anti-inflammatory responses. A and B,
pretreatment of macrophages with PP2, GSI-I, or LY294002, or chelerythrine, U0126, or p38 MAP kinase inhibitor or Bay 11-7082 abrogates MDP triggered
secretion of PGE2 (A) and IL-10 (B) (mean S.E., n 3).Med, medium; *, p 0.05 versusMDP.
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DISCUSSION
Activated macrophages have long been classified as the
most potent inflammatory cells in the body. However, recent
reports have suggested pivotal anti-inflammatory functions of
macrophages upon activation by different stimuli (38). In this
regard, receptors belonging to the pattern recognition recep-
tor family, in particular TLRs and NLRs, are critical innate
molecular sensors of surreptitious entry of intruding patho-
gens and make a platform for initiation and execution for effi-
cient immune responses (2). In this perspective, although
TLRs are largely believed to be pro-inflammatory, NLRs like
NOD2 have been implicated in regulation of anti-inflamma-
tory responses as well as polarization of T cells toward the
skewed Th2 phenotype (3, 6, 8). Intriguingly, certain disease
conditions characterized by heightened pro-inflammatory
responses, including Crohn disease, Blau syndrome, and
chronic inflammatory bowel disease are associated with mu-
tations in the functional NOD2 receptor, suggesting polymor-
phism in NOD2 predisposes the individual for a plethora of
inflammatory diseases (9). However, information about the
signaling cascades regulating a battery of genes associated
with NOD2-mediated cellular functions is still imprecisely
understood.
COX-2 has long been validated as a pro-inflammatory mol-
ecule and thus has been the target of many anti-inflammatory
drugs; however, recent reports have suggested a dual role for
COX-2 in the initiation as well as resolution of inflammation
(39–42). It has been advocated that COX-2 is critical for pro-
duction of electrophilic oxo-derivatives from the omega-3
fatty acids, which can act as peroxisome proliferator-activated
receptor- agonist and inhibit production of pro-inflamma-
tory cytokines (39, 41). Furthermore, 15-deoxy12–14PGJ2
(15d-PGJ2), a metabolite of PGD2 and crucial regulator of
anti-inflammatory responses through peroxisome proliferator-
activated receptor-, is elevated through the COX-2 pathway
in an animal model of acute inflammation (40, 42). In addi-
tion, the biosynthetic product of COX-2 activity, PGE2, is
known to regulate the expression levels of IL-10 (35). IL-10,
originally described as a cytokine synthesis inhibitory factor,
is a pleiotropic molecule with a crucial role in preventing in-
flammatory and autoimmune pathologies (43). It is well estab-
lished that IL-10 potently inhibits the production of soluble
mediators and cytokines, which hold the capacity to activate
as well as sustain inflammatory responses. By acting on innate
immune cells including macrophages and dendritic cells,
IL-10 inhibits the development of Th1 responses. Interest-
FIGURE 8. Signaling integration through cross-talk of the Notch1-PI3K and PKC-MAPK axis is critical for NOD2-mediated resolution of inflamma-
tion. A, quantitative real time PCR analysis for Bcl-xL, cIAP1, and XIAP expression upon stimulation of NOD2 with MDP, with or without pretreatment with
PP2, GSI-I, or LY294002 or chelerythrine, U0126, or p38 MAP kinase inhibitor or Bay 11-7082. B and C,MTT assay performed on TNF- (B) (200 ng/ml) or
IFN- (C) (1000 ng/ml) treated macrophages shows a significant decrease in apoptotic cells upon NOD2 stimulation with MDP. Pharmacological inhibition
of NOD2 (PP2), Notch1 (GSI-I), PI3K (LY294002), PKC (chelerythrine), or NF-B (Bay 11-7082) abrogated the suppressive effect of MDP. The data are repre-
sented as mean S.E. from three independent experiments.Med, medium; *, p 0.05 versusMDP; **, p 0.05 versus TNF- or IFN-; ***, p 0.05 versus
TNF-MDP or IFN-MDP.
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ingly, IL-10-deficient mice develop disease pathologies in the
murine model of inflammatory bowel disease (44). Impor-
tantly, a recent study demonstrated that COX-2/mice, but
not wild type mice developed Crohn disease-like pathology
associated with cellular infiltration, and decreased IL-10 ex-
pression in mice model of inflammatory bowel disease (45).
These observations eloquently advocate a paradigm shift in
understanding about the regulatory role of COX-2 during
inflammation and assign novel anti-inflammatory functions to
COX-2.
In the current investigation, we demonstrate that the cyto-
plasmic immune surveillance receptor, NOD2, is involved in
initiating innate immune signaling events that are important
for a diverse array of effector functions of the macrophages.
We observed that NOD2 receptor engagement resulted in
activation of Notch1 signaling, which required induced ex-
pression of the Notch1 ligand, Jagged1. We further demon-
strate that perturbations in expression of RIP2 or TAK1,
which are essentials for NOD2-mediated signaling, markedly
diminishes Notch1 signaling activation, and modulates the
expression of anti-inflammatory mediators like IL-10 and
COX-2/PGE2 as well as suppression of Notch1 signaling-me-
diated attenuation of TNF- or IFN--triggered apoptosis in
macrophages. These results suggest a multidimensional role
of NOD2 in regulation of a variety of cellular functions. Inter-
estingly, the ability of the NOD2 receptor to trigger robust
immunomodulatory molecular signatures was associated with
enhanced iNOS expression and NO production.
Several reports have suggested a critical link between
NOD2 and iNOS or NO production and it has been demon-
strated that NOD2 could trigger NO production in macro-
phages (46). Importantly, a recent report suggests that infec-
tion of RIP2 null mice with Chlamydophila pneumoniae
resulted in increased mortality due to a defect in generation of
effective NO production. This clearly ascribes a significant
and dominant role for NOD2/RIP2 signaling in induced ex-
pression of iNOS/NO, despite the presence of the intact TLR2
signaling module in RIP2-deficient mice or TLR2 agonists in
C. pneumoniae (47). NO act as a crucial molecular signal dur-
ing diverse pathophysiological conditions and NO/iNOS-me-
diated regulation of immunomodulatory gene expression in-
volves multiple pathways in macrophages (22). Differential
levels of NO flux depending on the state of activation as well
as initiation of specific signaling pathways often account for
elicitation of differential macrophage responses (48). In this
perspective, the local concentration and duration of NO ex-
posure serve as significant elements in regulation of a variety
of key genes involved in immune responses and macrophage
transition from execution of cellular apoptosis or matrix deg-
radation to cellular proliferation or matrix regeneration, pro-
cesses required for contraction of inflammatory responses
and wound healing (49). In the current study, we identified
NO as a pathological link between NOD2 and Notch1 that
may be pertinent to expression of key anti-inflammatory me-
diators like COX-2/PGE2, IL-10, or anti-apoptotic molecular
signatures like Bcl-xL, XIAP, and cIAP1. Upon NOD2/RIP2
signaling activation, the expression of Jagged1 is directly regu-
lated by NO, thus leading to positive regulation of Notch1
activation. We further demonstrate that the NOD2-driven
expression of COX-2 requires Notch1-mediated recruitment
of CSL/RBP-Jk and NF-B to the COX-2 promoter. Impor-
tantly, data from in vivo challenge experiments in mice clearly
implicate NO as a vital link in NOD2-triggered activation of
Notch1 signaling in vivo as specified by significantly enhanced
FIGURE 9.Model depicting NOD2-driven activation of the Notch1-PI3K and PKC-MAPK signaling integration axis.
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expression levels of activated Notch1, Jagged1, or COX-2 in
wild type mice compared with iNOS null mice.
Cellular responses of macrophages upon activation with a
wide variety of stimuli are often suggested to involve exten-
sive cross-talk between PI3K-AKT, PKC, MAPK, and NF-B
signaling cascades (20, 22, 50). In this perspective, NOD2-
triggered expression of COX-2 involved PKC-dependent acti-
vation of ERK1/2 and p38 MAPK. Interestingly, the ability of
NOD2 to induce activation of PKC, ERK1/2, and p38 MAPK
remained unaltered in iNOS null macrophages, conjecturing a
role for iNOS/NO independent mechanisms in regulation of
the PKC-MAPK signaling axis during NOD2 activation. In
addition, signaling perturbation data suggest that NOD2 trig-
gering brings signaling integration between iNOS/NO-
Notch1-PI3K and the PKC-MAPK signaling axis to activate
NF-B, which plays a crucial role in regulation of a multitude
of genes associated with modulation of inflammation includ-
ing COX-2, IL-10, Bcl-xL, cIAP1, and XIAP.
In conclusion, our study reveals that iNOS/NO is an essen-
tial link in NOD2-mediated activation of Notch1-PI3K signal-
ing, which can modulate a defined set of macrophage effector
functions. However, the PKC-MAPK signaling axis holds the
capacity to effectuate NOD2-mediated cellular functions in-
dependent of iNOS activity. This integrated cross-talk of
iNOS/NO, Notch1, PI3K, PKC, and MAPK downstream to
NOD2 can be of importance during diverse pro-inflammatory
pathological conditions like Crohn disease and inflammatory
bowel disease, as these signaling cohorts regulate the expres-
sion of a multitude of genetic signatures crucial for mounting
appropriate anti-inflammatory responses including COX-2,
IL-10, Bcl-xL, cIAP1, and XIAP (Fig. 9). Because, prevention
of exaggerated macrophage activation or stimulation of a pop-
ulation of anti-inflammatory macrophages holds the key to
minimize pro-inflammatory pathologies; our study provides
new insights into the understanding about the role of NOD2
in these pathologies and clearly paves a way toward the devel-
opment of novel therapeutics.
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Supplemental Table 1- Pharmacological reagents used in the study 
 
Pharmacological reagent Concentration 
AKT Inhibitor II (AKTi) 10μM 
Bay 11-7082 20μM 
Chelerythrine 1μM 
LY294002  10μM 
p38 MAP Kinase Inhibitor  1μM 
PKCαi  50μM 
PKCβi 20μM 
PKCδi 10μM 
PKCεi 50μM 
PKCζi 5μM 
PP2 500 nM 
Rapamycin 100nM 
RO31-8220 1μM 
SIN-1 20μM 
SP600125 50μM 
U0126 10μM 
Wortmannin 100nM 
γ-secretase inhibitor-I (GSI-I) 10μM 
 
 
Supplemental Table 2- Primer sequences used in the study 
 
Gene Forward 5'- 3' Reverse 5'- 3' 
GAPDH gagccaaacgggtcatcatct gaggggccatccacagtctt 
COX-2 gtatcagaaccgcattgcctc cggcttccagtattgaggagaacagat 
Notch1 agaatggcatggtgcccag tggtggagaggctgctgtgtag 
Jagged1 agaagtcagagttcagaggcgtcc agtagaaggctgtcaccaagcaac 
NOD2 caggtctccgagagggtactg gctacggatgagccaaatgaag 
RIP2 attccgcatcctgcatgaaat aacttcgtgattgagagagtgac 
TAK1 cggatgagccgttacagtatc gtccagattcactctgttgcttt 
IL-10 ggactttaagggttacttgggttgcc cattttgatcatcatgtatgcttct 
Bcl-xL gggatggagtaaactggggtc tgttcccgtagagatccacaaa 
XIAP cgagctgggtttctttataccg gcaatttggggatattctcctgt 
cIAP1 gcaactgggaaccaaaggatg ctcaatcgagcagagtgtgtc 
 
  
Supplemental FIGURE S1. Absence of non-specific effect of PP2 against Src in mouse 
peritoneal macrophages. A, PP2 failed to inhibit PMA induced activation of Src in mouse 
peritoneal macrophages. B, Stimulation of NOD2 by MDP does not trigger activation of Src. 
Med, Medium. Data is representative of two independent experiments.  
  
Supplemental FIGURE S2. siRNA mediated knockdown of target gene expression. A-D, 
Transient transfection of (A) NOD2 (B) RIP2 (C) TAK1 (D) Notch1 siRNA in RAW 264.7 cells 
abrogated the expression of NOD2, RIP2, TAK1 and Notch1 respectively. Data represents two 
independent experiments. 
 
 
 
 
 
 
Supplemental FIGURE S3. NOD2 activates Nocth1 signaling in mouse dendritic cells. A, 
Mouse bone marrow derived dendritic cells (BMDCs) were treated with RIP2 kinase inhibitor, 
PP2, prior to stimulation of NOD2 with MDP followed by analysis of protein levels of NICD, 
Jagged1 and COX-2 by immunoblotting. Data is representative of two independent experiments. 
Med, Medium. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Supplemental FIGURE S4. NOD2 triggered activation PKC-MAPK-NF-κB signaling 
axis. A, MDP induces activation of PKC and ERK1/2, p38 MAPK in mouse macrophages. B, 
Stimulation of NOD2 by MDP triggers nuclear translocation of p65 NF-κB. C, Treatment with 
Bay 11-7082, prior to NOD2 stimulation abolished COX-2 expression. The blots are 
representative of two independent experiments. Med, Medium.  
 
 
 
Supplemental FIGURE S5. Critical role for Notch1 in NOD2 mediated regulation of anti-
inflammatory responses. A, Inhibition of Notch1-PI3K and PKC-MAPK signaling axis abrogates 
NOD2 triggered expression of IL-10 in macrophages as analyzed by quantitative real-time PCR 
analysis. B and C, Pretreatment of mouse BMDCs with PP2 abolishes NOD2 induced secretion of 
(B) PGE2 and (C) IL-10. The data is represented as mean ± S.E. from three independent 
experiments. Med, Medium; *, p < 0.05 versus MDP. 
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